

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

## **FURTHER INFORMATION ON DISCLOSEABLE TRANSACTION IN RELATION TO ACQUISITION OF FACILITY ASSETS OF A BIOLOGICS DRUG PRODUCT MANUFACTURING PLANT**

Reference is made to the announcement of the Company dated January 16, 2020 in relation to the acquisition of the Facility Assets of the Manufacturing Plant located in Leverkusen, Germany (the “**Announcement**”). Terms used herein have the same meanings as those defined in the Announcement unless the context requires otherwise. This announcement is made to provide further information on the Transactions.

Pursuant to the Asset Purchase Agreement, the total consideration for the Acquisition is EUR77,000,000 (equivalent to approximately HK\$664,132,700), which shall be paid by WuXi Biologics Germany to Bayer (being a listed company whose shares are traded on the German Stock Exchanges) in cash at Completion. The base rent under the Sublease Agreement and the service fee under the Transitional Service Agreement are EUR1,750,000 (equivalent to approximately HK\$15,093,925) per annum (subject to annual adjustment based on the German consumer price index) and EUR115,000 (equivalent to approximately HK\$991,887) per month, respectively, which were determined after arm’s length negotiations between the parties with reference to, among others, the comparable rent of similar properties in the vicinity and the cost and expertise of Bayer for providing the services. Pursuant to IFRS16, the leasing of the Subleased Property will be recognized as right-of-use assets of approximately HK\$430.2 million, calculated with reference to the present value of the aggregated payments to be made under the Sublease Agreement, and the entry into of Sublease Agreement will be regarded as an acquisition of asset under the definition of transaction set out in Rule 14.04(1)(a) of the Listing Rules.

*Conversion of Euros into Hong Kong dollars is based on the exchange rate of EUR1.00 =HK\$8.6251*

By order of the Board  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, January 20, 2020

*As of the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.*

\* *For identification purpose only*